There are many challenges in the application of miRNA-based therapies.[32] For instance, miR-1 suppresses metastasis in HNSCC by targeting TAGLN2;[53] however, targeting MET, a proto-oncogene, is the underlying mechanism for anti-tumorigenic property of miR-1 in lung cancer. This evidence concerns the gene TAGLN2 and lung carcinoma.